Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.
J Intern Med. 2023 May;293(5):648-655. doi: 10.1111/joim.13616. Epub 2023 Feb 26.
J Intern Med. 2023.
PMID: 36843323
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystrøm CM, Torp R, Mielnik P, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA.
Syversen SW, et al. Among authors: brun mk.
JAMA. 2021 May 4;325(17):1744-1754. doi: 10.1001/jama.2021.4172.
JAMA. 2021.
PMID: 33944876
Free PMC article.
Clinical Trial.
Item in Clipboard
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA.
Syversen SW, et al. Among authors: brun mk.
JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316.
JAMA. 2021.
PMID: 34932077
Free PMC article.
Clinical Trial.
Item in Clipboard
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW.
Brun MK, et al.
J Intern Med. 2022 Sep;292(3):477-491. doi: 10.1111/joim.13495. Epub 2022 Apr 26.
J Intern Med. 2022.
PMID: 35411981
Free PMC article.
Clinical Trial.
Item in Clipboard
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.
Gehin JE, Goll GL, Brun MK, Jani M, Bolstad N, Syversen SW.
Gehin JE, et al. Among authors: brun mk.
BioDrugs. 2022 Nov;36(6):731-748. doi: 10.1007/s40259-022-00559-1. Epub 2022 Oct 31.
BioDrugs. 2022.
PMID: 36315391
Free PMC article.
Review.
Item in Clipboard
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
Brun MK, Gehin JE, Bjørlykke KH, Warren DJ, Klaasen RA, Sexton J, Sandanger Ø, Kvien TK, Mørk C, Jahnsen J, Bolstad N, Jørgensen KK, Haavardsholm EA, Goll GL, Syversen SW.
Brun MK, et al.
Lancet Rheumatol. 2024 Apr;6(4):e226-e236. doi: 10.1016/S2665-9913(23)00341-7. Epub 2024 Feb 22.
Lancet Rheumatol. 2024.
PMID: 38402891
Clinical Trial.
Item in Clipboard
Cite
Cite